Provided by Tiger Trade Technology Pte. Ltd.

Akari Therapeutics PLC

8.72
-0.1200-1.36%
Post-market: 8.720.00000.00%16:26 EDT
Volume:15.26K
Turnover:131.92K
Market Cap:16.98M
PE:-0.55
High:9.14
Open:9.01
Low:8.26
Close:8.84
52wk High:44.20
52wk Low:3.02
Shares:1.95M
Float Shares:694.50K
Volume Ratio:0.27
T/O Rate:2.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-15.9015
EPS(LYR):-20.5537
ROE:-140.09%
ROA:-19.10%
PB:0.91
PE(LYR):-0.42

Loading ...

Akari Therapeutics Plc - Aktx-101 Phase 1 First-in-Human Trial Targeted by Mid-2027

THOMSON REUTERS
·
May 12

Akari Therapeutics Plc - Granted Major European Patent for Ph1 ADC Payload Platform

THOMSON REUTERS
·
May 12

ADRs Close Lower; Akari Therapeutics PLC Declines 18%

Dow Jones
·
May 12

European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading

MT Newswires Live
·
May 11

Akari Therapeutics PLC expected to post a loss of $1.38 a share - Earnings Preview

Reuters
·
May 09

European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday Trading

MT Newswires Live
·
May 06

European Equities Traded in the US as American Depositary Receipts Start Week Lower

MT Newswires Live
·
May 04

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

MT Newswires Live
·
May 01

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading

MT Newswires Live
·
Apr 29

European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading

MT Newswires Live
·
Apr 27

BRIEF-Akari Therapeutics Secures Australian Patent Approval

Reuters
·
Apr 27

Akari Therapeutics wins Australian patent acceptance for Thailanstatin analog ADC payload

Reuters
·
Apr 27

Akari Therapeutics Plc - Aktx-101 in Ind-Enabling Studies With Phase 1 Trial Expected Late 2026/Early 2027

THOMSON REUTERS
·
Apr 27

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary Ph1 Rna Splicing Modulator ADC Payload

THOMSON REUTERS
·
Apr 27

European Equities Traded in US as ADRs Ease in Thursday Trading

MT Newswires Live
·
Apr 23

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

MT Newswires Live
·
Apr 21

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

GlobeNewswire
·
Apr 21

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live
·
Apr 20

Akari Therapeutics announces presentation of preclinical data for AKTX-101

TIPRANKS
·
Apr 20

Akari targets Q1 2027 start for Phase 1 trial of AKTX-101 ADC

Reuters
·
Apr 20